RX-3117: Phase Ib/IIa started

Rexahn began an open-label, U.S. Phase Ib/IIa trial to evaluate 700 mg oral RX-3117 given

Read the full 152 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE